New psoriasis drugs are more effective than current standard therapies
July 10, 2015 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];July 10, 2015 / Bio Valley BIOON / -- Recently, a research paper published in the international journal New England Journal of Medicine , researchers from Northwestern University conducted a phase II clinical trial, the results It shows that a psoriasis drug called guselkumab may be superior to current standard therapies for the treatment of chronic skin diseases. The researchers compared the efficacy of guselkumab and adalimumab, a commonly used drug. For the treatment of psoriasis drugs.
Researcher Dr. Kenneth Gordon said that our research aims to find a range of new drugs to help patients with the development of chronic skin diseases; psoriasis is an immune-mediated disease that causes it to itch, dry and red A rash, etc., also increases the risk of depression, heart disease and diabetes. Psoriasis currently affects nearly 3% of the world's health globally, and about half of all patients with psoriasis are not properly treated.
For patients, the disease will continue to accompany them. In a multicenter collaborative study conducted in this study, the researchers studied 293 patients with moderate to severe psoriasis and randomized patients to receive two drugs ( One or a placebo of the drug guselkumab and adalimumab was treated for up to 52 weeks. At 16 and 40 weeks of treatment, the researchers measured the efficiency of the drug treatment, ie 0-5, and showed that the drug guselkumab was taken compared to the adalimumab and placebo patients. Most of the patients in the treatment group scored 0 (complete psoriasis) or 1 (mild psoriasis). At 40 weeks of treatment, 81% of patients taking 200 mg dose of guselkumab per day scored 0. Or 1, and only 49% of patients taking adalimumab can achieve this score.
The researchers say the new drug works by blocking the function of interleukin 23, a key protein involved in the development of psoriasis. Gordon said that based on clinical and previous basic research, we will change the pathogenesis of psoriasis and The understanding of therapy, this study or we have proposed a new insight into the treatment of psoriasis, we are currently in the phase III clinical trial we will test the safety and effectiveness of the drug guselkumab.
Erythritol For Pharmaceutical,Erythritol Oligosaccharides,Naturally Sweet Erythritol,Erythritol On Keto Diet
Ningxia Eppen Biotec CO.,LTD , https://www.nxeppen.com